Badaoui 1999.

Study characteristics
Methods	Study design: randomized controlled trial Study grouping: 3 groups, monoprophylaxis
Participants	Baseline characteristics Placebo Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): NA Received treatment (n): NA Analysed (n): 50 Age (mean ± SD, median (IQR), median (range)): 51 ± 19 Weight (mean ± SD, median (IQR), median (range)): 72 ± 17 BMI (mean ± SD, median (IQR), median (range)): NA ASA I/II/III/IV (n): 30/15/5/0 Gender (female in %): 56 Non‐smoker (%): NA History of PONV/motion sickness (%): NA Type of general anaesthesia: balanced anaesthesia (isoflurane, N₂O, fentanyl) Duration of anaesthesia or surgery (in min; as mean or median): 62 Use of perioperative opioids (if yes, which?): intraoperative fentanyl 0.1 mg bolus as required Type of surgery: cholecystectomy, parotid, proctologic surgery, thyroidectomy, mastectomy, varicosectomy Droperidol Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): NA Received treatment (n): NA Analysed (n): 50 Age (mean ± SD, median (IQR), median (range)): 49 ± 16 Weight (mean ± SD, median (IQR), median (range)): 76.5 ± 16 BMI (mean ± SD, median (IQR), median (range)): NA ASA I/II/III/IV (n): 26/20/3/1 Gender (female in %): 50 Non‐smoker (%): NA History of PONV/motion sickness (%): NA Type of general anaesthesia: balanced anaesthesia (isoflurane, N₂O, fentanyl) Duration of anaesthesia or surgery (in min; as mean or median): 66 Use of perioperative opioids (if yes, which?): intraoperative fentanyl 0.1 mg bolus as required Type of surgery: cholecystectomy, parotid, proctologic surgery, thyroidectomy, mastectomy, varicosectomy Ondansetron Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): NA Received treatment (n): NA Analysed (n): 45 Age (mean ± SD, median (IQR), median (range)): 52 ± 15 Weight (mean ± SD, median (IQR), median (range)): 75 ± 17 BMI (mean ± SD, median (IQR), median (range)): NA ASA I/II/III/IV (n): 27/16/2/0 Gender (female in %): 53.3 Non‐smoker (%): NA History of PONV/motion sickness (%): NA Type of general anaesthesia: balanced anaesthesia (isoflurane, N₂O, fentanyl) Duration of anaesthesia or surgery (in min; as mean or median): 61 Use of perioperative opioids (if yes, which?): intraoperative fentanyl 0.1 mg bolus as required Type of surgery: cholecystectomy, parotid surgery, proctologic surgery, thyroidectomy, mastectomy, varicosectomy Included criteria: age over 18 years, elective surgery that "was considered emetogenic", ASA I to III Excluded criteria: NA Pretreatment: baseline characteristics (age, weight, ASA): no. Potential effect modifiers (gender, duration of anaesthesia): no; (history of PONV/motion sickness, non‐smoker, perioperative opioids): unclear
Interventions	Intervention characteristics Placebo Dose: 125 ml NaCl Time point of administration: 30 minutes before anaesthesia Route of administration: IV Rescue antiemetics (if yes, which?): NA Droperidol Dose: 1 mg Time point of administration: 30 minutes before anaesthesia Route of administration: IV Rescue antiemetics (if yes, which?): NA Ondansetron Dose: 4 mg Time point of administration: 30 minutes before anaesthesia Route of administration: IV Rescue antiemetics (if yes, which?): NA
Outcomes	Vomiting (0 to 24 hours) Outcome type: dichotomous outcome PONV (0 to 24 hours) Outcome type: dichotomous outcome
Identification	Sponsorship source: NA Country: France Setting: inpatient, single‐centre Author's name: D.R. Badaoui Institution: Department of Anesthesia Resuscitation B, Chu Nord Email: NA Address: Départment d'Anesthésie‐Réanimation B, CHU Nord, place Victor‐Pauchet, 80054 Amiens Cedex 01 Duration of study: February to July 1997 Language: French (2 reviewers: MSS, AA) Study's primary outcome: NA Trial registry number: NA
Notes	None
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Judgement comment: quote: "randomized" (translated). No further information on sequence generation provided
Allocation concealment (selection bias)	Unclear risk	Judgement comment: no statement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Judgement comment: quote: "double‐blind" (translated) Insufficient information on blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Judgement comment: quote: "double‐blind" (translated) Insufficient information on blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Judgement comment: it is stated that 150 participants have been included and 145 CRFs were analysable. No reasons/further information for exclusion of the 5 participants, which apparently have been all in the ondansetron arm, are provided
Selective reporting (reporting bias)	Unclear risk	Judgement comment: no reference to a study protocol or trial registry number reported
Other bias	Unclear risk	Judgement comment: baseline characteristics (age, weight, ASA): no. Potential effect modifiers (gender, duration of anaesthesia): no; (history of PONV/motion sickness, non‐smoker, perioperative opioids): unclear